Navigation Links
Lithium Beats Valproate for Long-Term Bipolar Therapy
Date:12/23/2009

Combined treatment or monotherapy with lithium helps prevent relapse, study finds

WEDNESDAY, Dec. 23 (HealthDay News) -- People with bipolar I disorder will do best over the long term with lithium treatment alone or a combination of lithium and valproate compared to valproate alone, new research suggests.

Patients who underwent the lithium or lithium/valproate treatments were less likely to relapse regardless of how severe their conditions were at the beginning of treatment, the study authors reported in the Dec. 22 online edition of The Lancet.

But the researchers couldn't say if the combined treatment is better or worse than lithium alone.

People with bipolar disorder have trouble regulating their moods and can swing between highs and lows. In most cases, patients have illness that is chronic or recurs over time. Doctors often prescribe combinations of drugs for these patients after single drugs fail to work, according to background information in a news release about the study.

The new study looked at 330 patients aged 16 and older with bipolar I disorder. The study participants lived in several countries, including the United States, and were randomly assigned to receive lithium, valproate or a combination of both drugs. They were followed for up to two years.

The results show that "for people with bipolar I disorder for whom long-term therapy is clinically indicated, combination therapy with lithium plus valproate is more likely to prevent relapse than is monotherapy with valproate. The 41 percent relative benefit is irrespective of baseline severity of illness, is maintained for up to two years, and is most apparent in prevention of manic relapse," the researchers concluded.

More information

The U.S. National Institute of Mental Health has more on bipolar disorder.



-- Randy Dotinga



SOURCE: The Lancet, news release, Dec. 22, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Possible genetic predictor for response to lithium augmentation in depressed patients
2. Lithium chloride slows onset of skeletal muscle disorder
3. Researchers Test Lithium as Radiation Protector
4. Study: HPV test beats Pap in detecting cervical cancer
5. Ultrasound Beats Blood Test for Gauging Ovarian Cancers: Study
6. Honey Beats Meds at Soothing Kids Cough
7. Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay
8. Experimental Therapy Beats Back One Patients Melanoma
9. Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income
10. Colonoscopy Beats Camera Pill at Catching Colon Cancer
11. Newer Drug Beats Tamoxifen for Older Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... (PRWEB) , ... May 21, 2017 , ... ... if it's been longer than six months since you've seen a dentist, it's ... twice per year and getting x-rays once per year. , Dental checkups are ...
(Date:5/19/2017)... ... May 19, 2017 , ... When Kyle Busch graduates from ... will already appear on two major research studies that could impact the health of ... Matt Daggett, KCU alumnus and an orthopedic surgeon, alongside an international team trying to ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Arnold ... Young Investigators: , Victor Acosta, Ph.D. - University of New Mexico, Jeremy Baskin, ... - University of Washington, Erik Grumstrup, Ph.D. - Montana Stata University, A. Fatih ...
(Date:5/19/2017)... ... 2017 , ... CloSYS products which are marketed as the gentle giants of ... and gum health, which is linked to one’s overall health. Since 1991 when the ... powerful ways in which CloSYS products immediately helped eliminate bad breath as well as ...
(Date:5/18/2017)... ... ... Originally launched to market as the EPIK Learning Tab, the highly successful ... of their product line, the company believed it was the right time to create ... be any tablet product sold by EPIK Learning. This year there will be ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
(Date:5/10/2017)... May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of the ... based on extensive data analysis from GHI,s hospitals database ... database for the region. The GHI database covers 86% of ... more than 130 data points for each institution in key ...
(Date:5/9/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... announced it has earned a spot on Forbes, ... Company was ranked among 500 U.S. employers as well ... Equipment and Services. The annual Forbes ... independent survey of over 30,000 employees across 25 industries. ...
Breaking Medicine Technology: